FDA suspends review of Datascope applications:
This article was originally published in Clinica
The US FDA has suspended substantive review of marketing applications for products manufactured by Datascope's Patient Monitoring Divison and InterVascular pending assessment of the validity of data. The company informed the agency last year of certain regulatory issues discovered during the course of an internal audit (see Clinica No 642, p 12). The FDA's Application Integrity Policy does not apply to the company's Collagen Products Division, which manufactures VasoSeal. Approval of a PMA for VasoSeal was recommended for use in coronary angiography and angioplasty procedures by the FDA's Circulatory System Devices Panel on May 8th (see this issue page 1). The percutaneous device is used to achieve haemostasis after catheterisation procedures involving puncture of the femoral artery.
You may also be interested in...
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.
A lower first dose boosted the vaccine’s efficacy result, but AstraZeneca has conceded that this has to be proven in a separate trial. In the meantime, the UK government has asked the regulator to assess the vaccine under a special health emergency provision.